Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic BP reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Clinical Endocrinology News)
SAN DIEGO (MedPage Today) — A combination of phentermine and topiramate (Qnexa) appears to induce weight loss and a decrease in metabolic risk parameters for cardiovascular disease in obese patients, researchers reported here. (Source: MedPage Today Endocrinology)
MedWorm Message: Register for MedMatcha, MedWorm’s m edical advertising network, and receive $5 free advertising.
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Family Practice News)
Lannett Company, Inc. (NYSE AMEX: LCI) announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ( ANDA) for Phentermine Hydrochloride Blue/White Seed Capsules USP, 30 mg, the generic equivalent of Sandoz, Inc.’s Reference Listed Drug (RLD) Phentermine Hydrochloride Capsules USP, 30 mg. According to Wolters Kluwer, U.S. sales of Phentermine Hydrochloride Capsules USP, 30 mg (more…)
GAITHERSBURG, Md. (MedPage Today) — An FDA advisory panel was divided over whether to recommend the approval of the investigational weight-loss drug phentermine/topiramate (Qnexa), but the Nay votes prevailed 10-6. (Source: MedPage Today Public Health)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and re ceive $5 free advertising.
Source: PharmaTimes
Area: News
PharmaT imes reports that advisers to the United States US Food and Drug Administration have voted 10-6 against recommending approval of the drug Qnexa® (phentermine/topiramate) for the treatment of obesity. Although the advisory panel did not dispute the effectiveness of the drug, the panel felt that the potential side effects such as depression, memory loss, increased heart rate and birth defects outweighed (more…)
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Cardiology News)
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment…
For complete story visit theheart.org. (Source: theHeart.org)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free adver tising.
The Food and Drug Administration approved Lannett Co. Inc.'s application to market a generic 30-milligram version of a medication for the short-term management of obesity called phentermine hydrochloride. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
MedWorm Message: Register for MedM atcha, MedWorm’s medical advertising network, and receive $5 free advertising.